Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥8.72B | ¥7.27B | +19.9% |
| Operating Income | ¥0.41B | ¥0.68B | −39.1% |
| Ordinary Income | ¥0.38B | ¥0.64B | −40.4% |
| Net Income | ¥0.25B | ¥0.39B | −37.5% |
| ROE | 10.0% | 16.6% | - |
Executive Summary
The cumulative results for Q3 of FY2026 showed a significant decline in profit despite higher revenue, due to deteriorating profit margins. Revenue increased to ¥8.72B (+19.9% YoY), while Operating Income fell substantially to ¥0.41B (-39.1%), Ordinary Income to ¥0.38B (-40.4%), and Net Income attributable to owners of the parent to ¥0.25B (-37.5%). Although the Primary Care Home Business (+42.0%) drove revenue growth, the business shifted to a segment loss, while profitability also declined in the core Home-Visit Pharmacy Business. Consequently, the quality of revenue growth is low.
Factors Affecting Performance
【Revenue】Revenue was ¥8.72B, up +19.9% YoY. By segment, the Home-Visit Pharmacy Business was the largest at ¥6.17B (70.8% of total revenue, +16.2% YoY), followed by the Primary Care Home Business at ¥1.66B (19.0% of total revenue, +42.0% YoY) and the Kirari Prime Business at ¥0.89B (10.2% of total revenue, +12.0% YoY). Strong growth in the Primary Care Home Business boosted overall revenue growth.
【Profit and Loss】Cost of sales increased to ¥7.21B (+29.0% YoY), outpacing revenue growth. As a result, the gross profit margin declined to 17.4%, and gross profit fell 10.2% YoY to ¥1.51B. Consequently, the operating margin contracted to 4.7% (approximately 450bp lower than in the same period of the previous year). Ordinary Income was ¥0.03B below Operating Income, mainly due to a ¥0.04B increase in interest expenses. The company recorded an impairment loss of ¥0.0004B as an extraordinary loss in the Home-Visit Pharmacy Business, compared with ¥0.0045B in the previous year. The company is experiencing a pattern of higher revenue but lower profit, with rising costs and the expansion of low-profitability businesses weighing on earnings.
Segment Analysis
The Kirari Prime Business generated revenue of ¥0.89B (+12.0% YoY) and segment profit of ¥0.52B (+11.4% YoY), with a profit margin of 58.3%, and remains the largest contributor to profit. The Home-Visit Pharmacy Business was the largest segment by revenue at ¥6.17B (+16.2% YoY), but segment profit declined 21.2% YoY to ¥0.39B, resulting in a lower profit margin of 6.3% and confirming a deterioration in profitability. The Primary Care Home Business achieved strong revenue growth of 42.0% YoY to ¥1.66B, but segment profit turned to a loss of ¥0.01B from a small profit in the same period of the previous year, as upfront costs associated with expanding locations weighed on profitability. Company-wide expenses (adjustments) totaled ¥0.45B, absorbing a substantial portion of segment profit.
Key Financial Metrics
【Profitability】The Operating Income margin of 4.7% and Net Profit margin of 2.8% both declined significantly from the approximate levels of 9.2% and 5.4%, respectively, in the same period of the previous year, mainly due to the compression of the gross profit margin to 17.4%. 【Cash Quality】Accounts receivable amounted to ¥2.51B, representing 29.0% of total assets, and increased at a rate exceeding revenue growth. This raises concerns about delays in cash collection relative to revenue growth. 【Investment Efficiency】ROE was 10.0% (equivalent to 9.9% on an annualized basis), indicating a structure in which the contribution of financial leverage is greater than that of profitability itself. 【Financial Soundness】The Equity Ratio was 28.6%, down from 33.6% in the previous year. Interest-bearing debt totaled ¥3.04B, primarily consisting of ¥2.24B in long-term borrowings, indicating increased reliance on debt.
Cash Flow Analysis
Because cash flow statement figures are not included in the disclosed data, funding trends are assessed based on changes in the balance sheet. Cash and deposits increased to ¥0.95B from ¥0.57B in the same period of the previous year, while accounts receivable rose significantly to ¥2.51B from ¥1.87B in the previous year, expanding at a pace exceeding revenue growth. Inventories totaled ¥0.25B and represented a small proportion of total assets, suggesting that the expansion of working capital was primarily attributable to the increase in accounts receivable. Fixed assets expanded to ¥4.83B, with property, plant and equipment increasing to ¥3.76B from ¥3.31B in the previous year, indicating continued investment associated with the expansion of business locations. These investments and the expansion of working capital have been supported by an increase in long-term borrowings (¥2.24B, compared with ¥2.03B in the previous year). Both the speed at which profit is converted into cash and the funding structure will influence the company’s future cash-generating capacity.
Earnings Quality
Ordinary Income declined to ¥0.38B from Operating Income of ¥0.41B due to interest expenses of ¥0.04B and other burdens. This difference reflects recurring financial expenses inherent in the business structure rather than a temporary factor. The company recorded an impairment loss of ¥0.0004B as an extraordinary loss in the Home-Visit Pharmacy Business, but this was lower than the ¥0.0045B recorded in the same period of the previous year, limiting its impact on current-period profit. Comprehensive income was ¥0.25B, broadly in line with Net Income attributable to owners of the parent of ¥0.25B. No significant divergence attributable to valuation differences on other securities or similar items was observed, indicating that earnings quality generally reflects the substance of the income statement. However, the fact that the increase in accounts receivable exceeded revenue growth warrants attention from an accrual perspective, as recorded profits may be preceding actual cash collection.
Earnings Forecast and Guidance
The cumulative Q3 progress rates against the full-year forecasts were 71.5% for Revenue, 41.2% for Operating Income, 39.4% for Ordinary Income, and 37.2% for Net Income. Revenue progress was close to the level implied by the passage of 9 months (75%), while profit progress was substantially lower. To achieve the full-year forecasts of ¥1.00B in Operating Income and ¥0.96B in Ordinary Income, approximately ¥0.59B in additional Operating Income will need to be generated in Q4. The company revised its earnings forecasts during the quarter and expects full-year Revenue to increase +22.1% YoY, while Operating Income is expected to decline 4.9% YoY and Ordinary Income 5.7% YoY. The extent to which profit margins recover in Q4 will be the key determinant of whether the full-year forecasts are achieved.
Shareholder Returns
The Q2 dividend was ¥0 per share, while the full-year dividend forecast is ¥20 per share. Based on the full-year Net Income forecast of ¥0.664B, the forecast Payout Ratio is approximately 21.4%, indicating reasonable dividend capacity assuming the earnings forecast is achieved. However, the cumulative Q3 progress rate for Net Income was only 37.2%, and if the full-year forecast is revised downward, the actual Payout Ratio may increase. No revision was made to the dividend forecast during the quarter, and the existing policy remains in place at present. Information regarding share repurchases is not included in the disclosed data.
Risk Factors
-
Deterioration in the profitability of the Primary Care Home Business: Revenue grew strongly by +42.0% YoY, but segment profit turned into a loss of ¥0.01B. The duration of upfront costs associated with expanding locations will affect the timing of monetizing growth investments.
-
Rising financial leverage: Interest-bearing debt totaled ¥3.04B, while the Equity Ratio declined to 28.6% from 33.6% in the previous year, indicating increased reliance on debt. Interest expenses increased to ¥0.04B and reduced Ordinary Income by ¥0.03B from Operating Income, creating a structure in which changes in the interest-rate environment are more likely to affect profit.
-
Extension of the accounts receivable collection period: Accounts receivable totaled ¥2.51B, representing 29.0% of total assets, and increased significantly from ¥1.87B in the previous year. The increase in accounts receivable exceeding revenue growth suggests a greater working capital burden accompanying revenue growth.
Industry Benchmark (For Reference; Company Analysis)
Industry Benchmark (retail)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 4.7% | 3.2% (0.7%–6.8%) | +1.5pt |
| Net Profit Margin | 2.8% | 1.4% (0.1%–4.4%) | +1.5pt |
Both the Operating Income margin and Net Profit margin exceed the industry median, indicating that profitability is relatively strong within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 19.9% | 3.0% (1.2%–10.3%) | +16.8pt |
The Revenue growth rate is substantially above the industry median, positioning the company among the high-growth companies in the industry.
※Source: Company analysis
Key Takeaways from the Earnings Results
-
Operating Income declined 39.1% despite a 19.9% increase in revenue, a significant divergence that highlights the structural importance of the decline in the gross profit margin to 17.4% and ongoing changes in the cost structure behind the growth.
-
While the Kirari Prime Business (58.3% profit margin) continues to serve as a core profit contributor, the rapidly growing Primary Care Home Business has shifted to a segment loss, resulting in greater variation in profitability across the business portfolio.
-
The profit progress rate against the full-year forecast (41.2% for Operating Income) is substantially below the Revenue progress rate (71.5%), making the presence or absence of a recovery in profit margins in Q4 the key determinant of full-year results.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and investors should consult with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q3 results show strong top-line expansion but a material deterioration in profitability. Nine-month revenue rose 19.9% year on year to ¥8.718bn. Operating income fell 39.1% to ¥411m despite the revenue increase. Ordinary income declined 40.4% to ¥380m, while net income decreased 37.5% to ¥246m. The gross margin compressed by 580bp year on year to 17.4% from 23.2%. The operating margin compressed by 457bp to 4.7% from 9.3%. The net profit margin contracted by 260bp to 2.8% from 5.4%. Cost of sales increased 29.0%, substantially faster than revenue growth, and was the principal driver of margin pressure. SG&A expenses rose 9.1%, slower than revenue, indicating that the earnings shortfall was concentrated in gross-profit generation rather than broad overhead inflation. The home-visit pharmacy business remained the largest revenue contributor, generating ¥6.165bn of sales, but its segment profit declined 21.2% to ¥386m. Primary Care Home revenue expanded 42.0% to ¥1.661bn, but the segment turned to a ¥15m loss from a ¥190m profit a year earlier. Kirari Prime increased segment profit 11.4% to ¥520m and remains the highest-margin operating segment. The reported annualized ROE was 13.2%, a solid level, but it was supported by 3.50x financial leverage rather than a strong net margin. Interest coverage of 10.47x remains adequate, although leverage is elevated at a 2.50x debt-to-equity ratio. The company has revised its full-year forecast, and Q3 revenue progress is broadly consistent with the revised sales target while profit progress is behind the normal seasonal run rate. The FY forecast implies a substantial Q4 recovery in operating income, making restoration of gross margin and Primary Care Home profitability the central issues for the remainder of the year.
Profitability Analysis
The reported annualized 13.2% ROE decomposes into a 2.8% net profit margin, 1.341x asset turnover, and 3.50x financial leverage. The weakest component is the 2.8% net margin, which is below the 3% concern threshold and declined from approximately 5.4% in the prior-year nine-month period. Financial leverage is the principal support for ROE: assets are 3.50x equity, compared with a substantially lower capital cushion implied by the prior-period balance sheet. The annualized 1.341x asset turnover indicates reasonable revenue generation from the asset base, but it cannot offset the severe margin compression. Gross margin fell to 17.4% from 23.2%, a 580bp decline, because cost of sales grew 29.0% against 19.9% sales growth. Operating margin fell to 4.7%, below the 5% efficiency warning level, even though SG&A grew only 9.1% and therefore declined as a percentage of revenue. This indicates negative gross-profit operating leverage rather than uncontrolled corporate-cost growth. The five-factor DuPont interest burden was 0.917, showing that interest expense reduced pre-tax income but has not yet become an acute earnings constraint. The tax burden was 0.653, equivalent to a 34.5% effective tax rate, and therefore tax was not the principal cause of the profit decline. Segment-level profitability was highly polarized: Kirari Prime generated a 58.3% segment margin, broadly stable year on year, while home-visit pharmacy generated a 6.3% segment margin, down from 9.2%. Primary Care Home shifted from a 16.2% segment margin to a negative 0.9% margin. Consolidated operating income also bears ¥453m of unallocated corporate costs, nearly unchanged from ¥464m a year earlier, so the year-on-year decline principally reflects lower segment profit. A ¥4m impairment loss was recorded in home-visit pharmacy, well below the prior-year ¥45m impairment and not material to the underlying operating-margin deterioration. Under JGAAP, the available data show intangible assets of ¥410m, or 4.7% of total assets, which does not indicate an unusually intangible-heavy balance sheet.
Growth Assessment
Revenue growth of 19.9% was broad-based across the three reported operating segments. Home-visit pharmacy sales increased 16.2% to ¥6.165bn and represented 70.7% of consolidated revenue, making it the core business by revenue contribution. Kirari Prime sales rose 12.0% to ¥892m. Primary Care Home was the fastest-growing business, with sales up 42.0% to ¥1.661bn. However, the growth mix has reduced near-term earnings quality because the fastest-growing Primary Care Home segment became loss-making. Home-visit pharmacy's segment-profit decline of 21.2% despite double-digit sales growth also signals cost, pricing, or operating-efficiency pressure within the core business. Kirari Prime was the only major segment to deliver both revenue and profit growth, with segment profit rising to ¥520m from ¥467m. Segment profit before corporate costs fell 22.0% to ¥865m, while corporate costs declined only 2.3%, resulting in the 39.1% fall in consolidated operating income. Against the revised full-year forecast, Q3 revenue progress is 71.5% versus the normal 75% level, a modest 3.5 percentage-point shortfall. Operating-income progress is 41.1% versus 75%, a 33.9 percentage-point shortfall. Ordinary-income progress is 39.4% versus 75%, a 35.6 percentage-point shortfall. Net-income progress is 37.2% versus 75%, a 37.8 percentage-point shortfall. The full-year forecast therefore requires Q4 operating income of ¥589m, exceeding the entire ¥411m delivered in the first nine months. The revenue forecast of ¥12.194bn implies Q4 sales of ¥3.475bn, so forecast delivery depends much more on margin recovery than revenue acceleration.
Financial Health
Liquidity is adequate but not abundant. The current ratio is 121.6%, above 1.0x, and the quick ratio is 113.6%, indicating that current obligations are covered by cash and receivables without reliance on inventory liquidation. Working capital was positive at ¥682m. Cash and deposits increased 68.4% year on year to ¥953m. Accounts receivable increased 34.1% to ¥2.511bn and represented 29.0% of total assets. Receivable days of 79 exceed the 60-day alert threshold, requiring close monitoring of collections and payer timing. Inventories rose 57.1% to ¥253m, although inventory remains only 2.9% of total assets. Accounts payable increased 43.9% to ¥1.088bn, partly financing the expansion in receivables and inventory. Interest-bearing debt totaled ¥3.039bn, comprising ¥800m of short-term loans and ¥2.239bn of long-term loans. Short-term debt represents 26.3% of interest-bearing debt, and cash covers short-term loans by 1.19x, mitigating immediate refinancing pressure. However, the debt-to-equity ratio is 2.50x, above the 2.0x warning threshold, and explicitly indicates aggressive debt funding relative to the equity base. Debt accounted for 55.1% of total capital, elevated but below the 60% covenant concern marker. Total liabilities were 71.4% of assets and equity represented 28.6% of assets, down from 33.6% a year earlier, showing a reduced loss-absorption buffer. Interest coverage of 10.47x is currently strong, but lower operating profit would reduce this cushion if margin pressure persists. Asset retirement obligations were ¥106m, representing a long-term fixed-site commitment that should be considered alongside lease and facility expansion decisions.
Notable B/S Changes
Cash and deposits: +¥387m (+68.4%) to ¥953m - improved cash liquidity and increased coverage of short-term loans to 1.19x. Trade receivables: +¥638m (+34.1%) to ¥2.511bn - receivables now account for 29.0% of assets; the associated 79-day collection period heightens working-capital and collection risk. Inventories: +¥92m (+57.1%) to ¥253m - inventory growth exceeds revenue growth, although inventories remain a modest 2.9% of total assets. Trade payables: +¥332m (+43.9%) to ¥1.088bn - supplier credit is helping finance operating-capital growth, but raises the importance of stable payment terms and cash conversion.
Cash Flow Quality
Dividend Sustainability
The revised full-year dividend forecast is ¥20 per share, while the Q2 dividend was ¥0 per share, indicating an expected year-end-oriented distribution. Based on forecast EPS of ¥93.15, the forecast dividend payout ratio is 21.5%. This is well below the 60% sustainability benchmark and leaves considerable accounting earnings retention capacity. Forecast net income of ¥664m exceeds the implied dividend requirement of approximately ¥143m based on 7.13m average shares. Retained earnings totaled ¥2.226bn, supporting balance-sheet capacity for the proposed distribution. The low payout ratio is prudent given the 2.50x debt-to-equity ratio and the need to restore profitability in the primary care home business.
Risk Assessment
Business risks include Core home-visit pharmacy profitability risk: revenue increased 16.2%, but segment profit fell 21.2% and the segment margin declined to 6.3% from 9.2%., Primary Care Home execution risk: the segment grew revenue 42.0% but moved from a ¥190m profit to a ¥15m loss, indicating that growth is currently not converting into earnings., Healthcare service reimbursement, labor-cost, staffing availability, and patient-volume risk: these factors can pressure gross margin in home-visit pharmacy and care-home operations., Low gross-margin risk: the 17.4% gross margin is below the 20% quality-alert threshold and fell 580bp year on year as cost of sales outpaced revenue., Receivable collection risk: receivable days of 79 are above the 60-day alert threshold, while trade receivables increased 34.1% to ¥2.511bn..
Financial risks include High leverage risk: the 2.50x debt-to-equity ratio exceeds the 2.0x warning level. This debt-funded capital structure amplifies ROE but also increases sensitivity to earnings volatility and interest costs., Margin and interest-servicing risk: EBIT margin is 4.7%, below the 5% warning level. Interest coverage remains adequate at 10.47x, but further EBIT contraction would narrow debt-service capacity., Capital-buffer risk: the equity ratio declined to 28.6% from 33.6% in the prior period, while liabilities reached 71.4% of assets., Working-capital financing risk: growth in receivables and inventory has been accompanied by a 43.9% rise in payables, increasing dependence on effective operating-capital management..
Key concerns include The largest risk to the FY outlook is the implied Q4 operating-income requirement of ¥589m, compared with ¥411m generated in the first nine months., The strongest likelihood-by-impact concern is failure to reverse gross-margin compression, since cost of sales grew 29.0% versus 19.9% revenue growth., The highest-impact segment concern is whether Primary Care Home can regain profitability while maintaining rapid expansion., The high-leverage quality alert is material rather than merely structural: 3.50x financial leverage is the primary support for the 13.2% annualized ROE, while underlying net margin is only 2.8%., The high-receivable-days alert merits ongoing scrutiny because a collection slowdown could constrain liquidity despite a current ratio above 1.0x..
Investment Implications
Key takeaways include Sales growth remains robust at 19.9%, led by Primary Care Home and home-visit pharmacy., Profitability has weakened materially, with gross, operating, and net margins down 580bp, 457bp, and 260bp, respectively., Kirari Prime is the highest-margin and most resilient segment, with segment profit up 11.4% year on year., Home-visit pharmacy remains the core business by revenue but experienced a significant segment-margin decline., The revised full-year forecast depends on an unusually large Q4 profit recovery, rather than simply continued revenue growth., Balance-sheet liquidity is adequate, but leverage is aggressive at 2.50x debt to equity and should be assessed alongside the declining equity ratio..
Metrics to watch include Consolidated gross margin and operating margin, Home-visit pharmacy segment margin, Primary Care Home segment profit or loss and margin, Q4 operating income versus the ¥589m implied requirement, Trade receivables and receivable days, Interest-bearing debt, debt-to-equity ratio, and interest coverage, Equity ratio and working-capital balance.
Regarding relative positioning, The company combines above-market healthcare-service revenue growth with weaker-than-desired consolidated operating efficiency. Its annualized ROE of 13.2% is within the good 10-15% range, but is lower quality than a margin-led return profile because it relies on 3.50x financial leverage. The 4.7% EBIT margin and 17.4% gross margin place current profitability below the stated efficiency benchmarks, while Kirari Prime provides a high-margin counterweight to pressure in the larger home-visit pharmacy and Primary Care Home operations.